The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression and hormone receptor status in breast cancer
- PMID: 14553848
- DOI: 10.1016/s0002-9610(03)00271-x
The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression and hormone receptor status in breast cancer
Abstract
Background: Neoadjuvant chemotherapy may decrease tumor volume to allow breast conservation surgery. Its effect on estrogen and progesterone receptor (ER/PR) expression and hormone receptor (HR) status is controversial.
Methods: From February 2001 to July 2002, 56 breast cancer patients treated with neoadjuvant chemotherapy and 56 non-neoadjuvant therapy (control) patients with adequate tissue samples were identified. Quantitative ER/PR expression was analyzed in preneoadjuvant or preoperative core biopsies and final surgical specimens. Changes between the two groups were compared to determine if alterations were due to neoadjuvant chemotherapy or tissue sampling.
Results: The ER/PR expression changed in 34 (61%) neoadjuvant chemotherapy patients and 27 (48%) control patients. These expression changes resulted in HR status (positive/negative) alterations in 3 patients (5%) in both groups. Age, histology, chemotherapy regimen, and neoadjuvant response did not predict change.
Conclusions: Hormone receptor status changed in 5% of neoadjuvant chemotherapy and control groups due to tissue sampling. As these changes may impact treatment, HR expression reanalysis in final surgical specimens is recommended.
Similar articles
-
Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.J BUON. 2013 Jan-Mar;18(1):57-63. J BUON. 2013. PMID: 23613389
-
Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy.Ann Surg Oncol. 2018 Nov;25(12):3535-3540. doi: 10.1245/s10434-018-6608-1. Epub 2018 Jul 6. Ann Surg Oncol. 2018. PMID: 29981025
-
[The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression in breast carcinoma].Zhonghua Wai Ke Za Zhi. 2005 Aug 1;43(15):1011-3. Zhonghua Wai Ke Za Zhi. 2005. PMID: 16194363 Chinese.
-
Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer.Cancer Treat Rev. 2011 Oct;37(6):422-30. doi: 10.1016/j.ctrv.2010.11.006. Epub 2010 Dec 21. Cancer Treat Rev. 2011. PMID: 21177040 Review.
-
Variability in hormone and growth factor receptor expression in primary versus recurrent, metastatic, and post-neoadjuvant breast carcinoma.Breast Cancer Res Treat. 2012 Aug;135(1):29-37. doi: 10.1007/s10549-012-2047-z. Epub 2012 Apr 8. Breast Cancer Res Treat. 2012. PMID: 22484731 Review.
Cited by
-
Clinical implications of receptor conversions in breast cancer patients who have undergone neoadjuvant chemotherapy.Breast Cancer Res Treat. 2023 Jul;200(2):247-256. doi: 10.1007/s10549-023-06978-0. Epub 2023 May 26. Breast Cancer Res Treat. 2023. PMID: 37233961 Free PMC article.
-
The association between mRNA expression of resistin, TNF- α, IL-6, IL-8, and ER-α in peripheral blood mononuclear cells and breast cancer.Turk J Med Sci. 2021 Jun;51(3):1345-1353. doi: 10.3906/sag-2008-292. Epub 2021 Jun 28. Turk J Med Sci. 2021. PMID: 33517609 Free PMC article.
-
Combinational Treatment of Doxorubicin With Neoadjuvant Docetaxel for Different Subtypes of Patients With Breast Cancer.Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820928435. doi: 10.1177/1533033820928435. Technol Cancer Res Treat. 2020. PMID: 32508292 Free PMC article.
-
HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation.J Pathol Transl Med. 2020 Jan;54(1):34-44. doi: 10.4132/jptm.2019.11.03. Epub 2019 Nov 6. J Pathol Transl Med. 2020. PMID: 31693827 Free PMC article. Review.
-
Response to immunohistochemical markers' conversion after neoadjuvant chemotherapy in breast cancer patients: association between imaging and histopathologic analysis.Clin Transl Oncol. 2020 Jan;22(1):91-102. doi: 10.1007/s12094-019-02112-z. Epub 2019 Apr 20. Clin Transl Oncol. 2020. PMID: 31006089
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials